It was a rare day in the life of a drug company in 2017, but in the case of Alnylam Pharmaceuticals, the company’s new blockbuster, it wasn’t the only buyer.
For $1.6 billion, a drug giant announced its first acquisition in more than five years: a medical device company, Alnyam Pharma.
Alnyams drug, called Oligoscerebellar, was approved in November for a rare type of cancer, called osteosarcoma, and has already been marketed to nearly a dozen patients.
But it’s still in its preclinical phase, and its price has not yet been set.
And as the company waits for its approval, its investors and analysts are starting to ask, what will happen when Oligo does go on sale?
Alnyamas sales manager, Ritter Pharmaceuticals , said the company would only go ahead with its plan to acquire Oligolif in 2018, and it will not have any further involvement in the product.
Alvylam will continue to own and operate the company, Ratteries said in a statement.
But the company has not said how much it is paying for OligoScerebro, which is expected to be a $1 billion deal.
The company will not be making any more acquisitions in 2017 or 2018, Rater said, adding that it will only continue to pursue other potential deals.
It’s been a busy year for drug companies, as the pharmaceutical industry has seen several big acquisitions in the past year.
In August, the United Kingdom’s Royal Free Pharma bought a pharmaceutical company called Alnyman, and in August, U.S. biotechnology giant Pfizer announced a $12 billion deal with Roche to sell Oligotel, a medical drug for bone cancer.
In February, the drug company Theranos said it was buying a pharmaceutical manufacturer called RIT for $5 billion.
And last month, the American Heart Association announced that it had secured a $3.6 million round of financing from Chinese investors, with the hope of developing new drugs that can treat heart disease.
For 2017, pharma companies also have been looking for ways to expand their business in 2017.
At least two drug companies announced new acquisitions this year, and one of them was the pharmaceutical company Alnyamy Pharma.
In January, Alnadyams first drug, Oligoblast, was launched to treat a rare form of Parkinson’s disease, and the company is looking for a partner to make the drug available to patients in the United States and other parts of the world.
Alnamy also announced that its new drug, Roxyzol, is a treatment for multiple sclerosis, and Alnalyams new drug is now being tested for a type of leukemia.
And in February, Alamy announced that, in the next three years, it will launch more than 60 drugs that will target cancer and cardiovascular disease.
“We see a lot of opportunity in the industry,” said Alnader, Almyas sales manager.
The big question that remains is whether the industry can find new ways to boost sales as new and innovative treatments emerge.
“It’s hard to forecast how the year will play out, but there are a lot more companies looking at the market in 2017 than we saw last year,” said David L. Himmelsbach, CEO of pharmaceutical research firm Gartner.
Alnadyam, Alvyams and Roche have a lot to gain from Oligoflavone, which could be an opportunity for drug makers.
The drug was approved for osteosarccoma and was priced at $8.4 million per pill.
In 2016, Alayams first-in-class treatment for the disease, Alyamolif, was sold for $4.7 million, and Roche sold Oligoromide, a treatment that uses the enzyme that helps make Altylactin digests sugar, for $3 million.
The companies expect to be able to make more of these drugs in the coming years.
“In the next few years, we’re going to see a whole new set of treatments come out, and we’re hoping that we can make an impact in the new year by offering these new drugs,” Alnam said in its statement.
Alayam is hoping to get a deal done with another pharmaceutical company in the first half of next year, but its plans are still being negotiated, Alvertshaham said.
Drug companies have had a lot on their plates this year.
They’ve had to deal with rising costs for healthcare, a global trade war and rising opioid abuse.
It is hard to predict what will be the next big story, said Ratterys.
“I think it will be a lot like the stock market, where the stock price is going up, and then